1,771.70
+6.77%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Rubicon Research
Its shares trade on NSE under the ticker RUBICON.NS. It has been listed since 16 October 2025. In the fiscal year to 31 March 2026, it reported revenue of ₹17.31bn and net income of ₹2.47bn. At that date it held total assets of ₹23.27bn and shareholders' equity of ₹12.89bn.
Rubicon Research Ltd. engages in the manufacturing and export of formulations spanning a diverse range of dosage forms and therapeutic areas. The company is headquartered in Thane, Maharashtra. The company went IPO on 2025-10-16. Its portfolio spans multiple dosage forms, including oral solids, oral liquids, nasal, and topical. Its technologies include RubiReten and RubiSRL. Its services include intellectual property evaluation and product design, formulation research development, analytical research development, technology transfer, dossier compilation and regulatory support, and clinical trials supplies. Its products are spread across many therapeutic areas, such as Analgesics/Pain Management, CVS, CNS, Hypokalemia, Skeletal Muscle Relaxants, NRT, Gastrointestinal, Metabolic, Immunosuppressant, and others. Others include Antipyretic, Hormonal Products, Diuretic, Antimuscarinics, Oral Rehydration Therapy, Over the Counter products, and Respiratory.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 16 Oct 2025
- Employees
- 1,141
- Website
- rubicon.co.in ↗
Leadership
Pay as last reported
- Mr. Venkat ChangavalliIndependent Non-Executive Chairman of the Board₹2.0m
- Mr. Parag SanchetiChief Executive Officer, Executive Director, since 2017₹23.1m
- Mr. Nitin JajodiaChief Financial Officer₹23.6m
- Ms. Deepashree TanksaleCompliance Officer, Company Secretary₹1.4m
- Ms. Pratibha PilgaonkarManaging Director, Executive Director, since 2000₹7.9m
- Mr. Shantanu RastogiNon-Executive Director
- Mr. Varun TalukdarNon-Executive Director
- Mr. Kumarapuram AnanthakrishnanIndependent Director₹2.0m
- Mr. Milind PatilIndependent Director₹2.2m
- Dr. Pradnya SaravadeAdditional Independent Woman Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Rubicon Research Ltd employs 1,141 full-time employees in Thane, Maharashtra.
- Rubicon Research Ltd offers diverse dosage forms including oral solids and topical products.
- Rubicon Research Ltd's portfolio spans therapeutic areas like Analgesics and CNS.
Weaknesses
- Rubicon Research Ltd's IPO listing date is 16 October 2025.
- Rubicon Research Ltd's headquarters city is Thane, Maharashtra.
- Rubicon Research Ltd's business description includes multiple therapeutic areas.
Opportunities
- Rubicon Research Ltd can expand its product range in Antipyretic and Hormonal Products.
- Rubicon Research Ltd can leverage RubiReten and RubiSRL technologies for new markets.
- Rubicon Research Ltd can grow in the Gastrointestinal and Metabolic therapeutic segments.
Threats
- Rubicon Research Ltd faces competition in the Analgesics/Pain Management segment.
- Rubicon Research Ltd must navigate regulatory challenges in the CNS therapeutic area.
- Rubicon Research Ltd's growth may be impacted by market saturation in NRT.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.